Innovent Biologics and Eli Lilly have signed an agreement for Innovent to handle importation, marketing, distribution, and promotion of Lilly's breast cancer drug Verzenios (abemaciclib) in mainland China. Lilly will continue manufacturing and product development. Verzenios is approved in China for various breast cancer treatments and is covered by national reimbursement, enhancing affordability. This partnership leverages Innovent's local market strength and Lilly's R&D expertise to improve access to this important therapy for breast cancer patients in China.
Eli Lilly reported a 56% year-over-year revenue increase to $19.8 billion in Q1 fiscal 2026, driven by its Zepbound and Mounjaro products, which will soon be covered by Medicare. The company posted non-GAAP earnings per share of $8.55, a 156% jump fr...
A bipartisan US congressional committee is investigating whether Merck, AbbVie, and three other major pharmaceutical companies conducted clinical trials in China that may have supported Chinese military capabilities. The inquiry focuses on due dilige...
The FDA has selected seven companies, including Eli Lilly and Regeneron, for its new PreCheck pilot program aimed at accelerating regulatory review of new pharmaceutical manufacturing facilities in the U.S. This program allows the FDA to review facil...
Starting July 1, Medicare will cover obesity drugs for eligible seniors through its new Bridge demonstration program, requiring a $50 monthly copay. This marks a major expansion in access to treatments from Novo Nordisk and Eli Lilly, previously unaf...
Eli Lilly's stock rose 7% in a single day, marking its largest gain since early February when it surged 10% after releasing 2025 results. The rise reflects broader gains in the healthcare sector but is notably driven by the company's advancements in ...
